Mattern Pharma

Mattern Pharma is a Swiss-based pharmaceutical company specializing in the development of innovative drug delivery systems, particularly for hormone replacement therapies. The company is best known for developing Natesto, the first and only FDA-approved nasal gel for testosterone replacement therapy in men with hypogonadism. Mattern Pharma focuses on optimizing the bioavailability and patient convenience of established compounds through its proprietary nasal delivery technology, which avoids the skin-to-skin transfer risks associated with topical gels. Beyond testosterone, the company has advanced programs for nasal progesterone targeting indications such as traumatic brain injury and reproductive health. Mattern Pharma operates primarily through a licensing model, partnering with other pharmaceutical firms for the late-stage development and commercialization of its assets.